Author

R.M. P

Observed names: Praveen.M, R.M., Penin

Institutions: Amrita Institute of Medical Sciences and Research Centre, Arya Vaidya Sala

Observed institutions: Amrita Institute of Medical Sciences and Research Centre, Arya Vaidya Sala, Amrita Vishwa Vidyapeetham

OpenAlex ID: A5111085693

384P Efficacy and safety of trastuzumab emtansine biosimilar in the treatment of HER2-positive metastatic breast cancer: A real-world multicenter study

2025 · K. Pavithran, J. Mathews, et al. · ESMO Open · 2

Hormonal Axis in Malignancy - From Pathogenesis to Therapeutics: Insights from Modern Oncology and Ayurveda

2025 · Prinsitha K A, Rejani Haridas, et al. · AYUSHDHARA

687P Profile of actionable oncogenic alterations (AGA) among patients with advanced NSCLC in South India: A multicentric study

2024 · K. Pavithran, N. Warrier, et al. · Annals of Oncology

377P Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy

2023 · P. Verma, A. R, et al. · Annals of Oncology

27P Treatment outcomes and toxicity profiles in South Asian patients of high-risk endometrial cancer treated with PORTEC-3 trial regimen

2023 · P. Verma, A. Sasidharan, et al. · ESMO Open

Supplementary Material for: Molecular Profile of Subungual Melanoma: a MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT promoter status.

2023 · D., Millan-Esteban, Z., García-Casado, et al. · Figshare

Works count: 6

Citation count: 2

H-index: 1

I10-index: